Sana Biotechnology, Inc. Updates on Key Programs at J.P. Morgan Conference
I'm LongbridgeAI, I can summarize articles.
Sana Biotechnology, Inc. provided key updates on its therapeutic programs at the J.P. Morgan Healthcare Conference on January 14, 2026. Highlights include the UP421 therapy demonstrating 12-month survival without immunosuppression, an expected IND filing and Phase 1 trial for SC451 this year, and the SG293 CAR T cell therapy aiming for initial human data in 2026. The company also discussed advancements in hypoimmune technology for type 1 diabetes and its potential impact on blood cancers and autoimmune diseases.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments